REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) reached a new 52-week high during trading on Thursday . The company traded as high as $12.30 and last traded at $12.22, with a volume of 972253 shares trading hands. The stock had previously closed at $10.51.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on RGNX shares. Chardan Capital reiterated a "buy" rating and issued a $52.00 price target on shares of REGENXBIO in a research report on Monday, September 8th. Barclays cut their target price on REGENXBIO from $50.00 to $37.00 and set an "overweight" rating on the stock in a research report on Friday, August 8th. Wall Street Zen lowered REGENXBIO from a "hold" rating to a "strong sell" rating in a research report on Saturday, August 9th. HC Wainwright restated a "buy" rating and set a $34.00 target price on shares of REGENXBIO in a research report on Tuesday. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of REGENXBIO in a research report on Wednesday. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, REGENXBIO presently has an average rating of "Moderate Buy" and a consensus price target of $28.38.
Get Our Latest Report on REGENXBIO
REGENXBIO Price Performance
The firm has a fifty day simple moving average of $9.14 and a 200-day simple moving average of $8.62. The firm has a market cap of $640.42 million, a P/E ratio of -3.69 and a beta of 1.17.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($1.13) by ($0.25). The company had revenue of $21.36 million during the quarter, compared to analysts' expectations of $40.87 million. REGENXBIO had a negative return on equity of 66.95% and a negative net margin of 112.70%. On average, equities analysts predict that REGENXBIO Inc. will post -4.84 earnings per share for the current year.
Insider Activity at REGENXBIO
In other news, CEO Curran Simpson sold 7,624 shares of the stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $10.03, for a total value of $76,468.72. Following the completion of the sale, the chief executive officer directly owned 236,973 shares of the company's stock, valued at $2,376,839.19. This represents a 3.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 12.79% of the stock is currently owned by company insiders.
Institutional Trading of REGENXBIO
Institutional investors and hedge funds have recently modified their holdings of the stock. Janney Montgomery Scott LLC purchased a new stake in shares of REGENXBIO during the first quarter valued at approximately $484,000. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of REGENXBIO during the first quarter valued at approximately $123,000. Acadian Asset Management LLC purchased a new stake in shares of REGENXBIO during the first quarter valued at approximately $1,123,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of REGENXBIO by 9.2% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 72,183 shares of the biotechnology company's stock valued at $558,000 after acquiring an additional 6,105 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in shares of REGENXBIO by 372.1% during the first quarter. GAMMA Investing LLC now owns 16,188 shares of the biotechnology company's stock valued at $116,000 after acquiring an additional 12,759 shares during the last quarter. 88.08% of the stock is owned by hedge funds and other institutional investors.
REGENXBIO Company Profile
(
Get Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
